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ABSTRACT: Nine new (1−9) and two known (10, 11)
jatrophane diterpenoids were isolated from the methanol
extract of Euphorbia dulcis. The structure elucidation of the
compounds was performed by means of extensive spectro-
scopic analysis, including HRESIMS, 1D (1H, JMOD), and
2D (HSQC, HMBC, 1H−1H-COSY, NOESY) NMR experi-
ments. The absolute conﬁguration of compound 1 was
determined by single-crystal X-ray diﬀraction. The electro-
physiological eﬀects of compounds 1−11 and the ﬁve
diterpenoids (12−16) previously isolated from Euphorbia
taurinensis were investigated on stable transfected HEK-
GIRK1/4 (Kir3.1/3.4) and HEK-hERG (Kv11.1) cell lines using automated patch-clamp equipment. The majority of the
diterpenoids showed signiﬁcant blocking activity on GIRK channels (60.8−88.7% at 10 μM), while compounds 1, 2, 9−11, 13,
and 14 exerted notable inhibitory eﬀects even at 1 μM concentration. None of the jatrophane diterpenoids interfered with the
function of hERG proteins; however, compound 14 remarkably hampered K+ ﬂow through hERG channels. These selective
activities suggest that jatrophane diterpenoids may represent a group of potential lead compounds for the development of novel
therapeutic agents against atrial ﬁbrillation.
Atrial ﬁbrillation (AF) is the most common form ofsustained cardiac arrhythmia in adults. It is characterized
by uncoordinated supraventricular activation and consequently
ineﬀective, quivering, or irregular atrial contractions.1 As a
prominent risk factor of life-threatening cardiovascular
conditions such as thrombo-embolism, stroke, and heart
failure, AF accounts for huge and rapidly growing healthcare
expenditures in Western countries.2,3 Despite the continuous
improvement of therapeutic strategies, AF still contributes to
an estimated 130 000 deaths each year just in the U.S.4
Current antiarrhythmic drugs (AADs) have numerous
disadvantages, most importantly the lack of atrial speciﬁcity
associated with an increased risk of side eﬀects and the poor
eﬃcacy rate (e.g., 50−60% for amiodarone, which is generally
considered as the most eﬀective AAD).5 This background
underlines the constant need for the development of more
targeted AADs.
Although the pathomechanism of AF is not yet fully
understood, it has been described that elevated vagal nerve
tone can induce ion-channel-mediated detrimental electro-
physiological alterations in the atrial muscle tissue.6 Ion
channels are pore-forming transmembrane proteins that are
classiﬁed into ligand-gated and voltage-gated groups. GIRK
channels (G protein-activated inwardly rectifying potassium
channels) are activated by acetylcholine and are involved in the
ﬁne electrical regulation of neurons, β-pancreatic cells, and
atrial myocytes. Malfunctions of GIRK proteins are suspected
to contribute to the development of neuropathic pain, drug
addiction, and cardiac arrhythmias.7 This hypothesis is
supported by recent animal studies in which tertiapin, a
peptide isolated from bee venom, terminated AF episodes by
prolonging the atrial eﬀective refractory period through
selective blockade of GIRK channels.8
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hERG channels (human ether-a-go-go-related gene encoded
potassium channels) are members of the K+-permeable
voltage-gated membrane proteins (“Kv channel class”)
frequently referred to as Kv11.1. hERG channels pass the
rapid component of delayed rectiﬁer K+ current (IKr) and thus
inﬂuences the duration of the plateau phase and the
pacemaking activity of sinoatrial and atriventricular node
cells.9 A wide range of structurally unrelated drugs such as
psychiatric, antimicrobial, antihistamine, and even antiarrhyth-
mic agents have been shown to possess strong aﬃnity toward
hERG channels.10,11 The consequent drug-induced QT
interval prolongation in the EKG predisposes patients to
Torsades de Pointes (TdP) arrhythmias and sudden cardiac
death. Several drugs have been withdrawn from the market
because of fatalities caused by prolonged QT and subsequent
TdP.12 Given the clinical importance of the proarrhythmogenic
potential of commonly used pharmaceuticals, screening drug
candidates for their hERG channel selectivity during preclinical
safety assessments is a common practice nowadays.
Natural products represent a vast source of compounds with
astonishing chemical and pharmacological diversity. Diterpe-
noids are characteristic secondary metabolites of Euphorbia-
ceae species with well-established multidrug-resistance-revers-
ing,13 antiproliferative,14 and antiviral properties.15 However, a
limited amount of data are available on their cardiac eﬀects.
Diterpenoids with myrsinane, premyrsinane, and cyclomyrsi-
nane skeletons isolated from Euphorbia falcata were described
as selective blockers of GIRK proteins,16 while daphnane-type
orthoesters of the active fraction of Gnidia polycephala exerted
hERG channel inhibitory activity.17 Our research group
reported for the ﬁrst time that jatrophane-type diterpenoids
from Euphorbia guyoniana are able to substantially prevent K+
ﬂow (IK,Ach) through GIRK channels.
18
Euphorbia dulcis L. is a perennial plant distributed in West
and Central Europe. Its chemical constituents have been barely
investigated; only four ﬂavonol glycosides were isolated from
the methanol extract of the plant.19 As part of the ongoing
phytochemical examination of Euphorbiaceae species, we
describe the isolation and structure determination of nine
new (1−9) and two known [euphomelliferene B (10),
euphornin (11); structures in the Supporting Information]
jatrophane diterpenoids. The GIRK channel inhibitory
activities of the isolated compounds and ﬁve additional
diterpenoids obtained from the methanol extract of E.
taurinensis,20 namely, 5-acetoxy-3,9-dicinnamoyloxy-15-hy-
droxy-14-oxojatropha-6(17),11E-diene (12), 3-O-angeloyl-20-
deoxyingenol (13), 3-O-angeloyl-17-angeloyloxy-20-deoxyin-
genol (14), 20-O-acetyl-3-O-angeloyl-17-angeloyloxyingenol
(15), and 6,14-diacetoxy-5-(2-acetoxyacetoxy)-3-benzoyloxy-
15-hydroxy-9-oxosegetane (16), were investigated on the
stable transfected HEK-GIRK1/4 (Kir3.1/3.4) cell line. The
most potent blockers of GIRK proteins were further tested for
their hERG-related cardiotoxicity on HEK-hERG (Kv11.1)
cells.
■ RESULTS AND DISCUSSION
Characterization of Compounds 1−11. Compound 1
was isolated as white, amorphous granules. The peak of the
protonated molecule displayed at m/z 625.3371 (calcd
625.3377) in the HRESIMS data suggested the molecular
formula C36H48O9. The
1H and JMOD spectra showed
distinctive signals of a benzoyl (δH 7.98 d, 7.49 t, 7.38 t; δC
165.8, 132.8, 130.4, 130.0, and 128.5), two acetyl (δH 2.19 s,
1,86 s; δC 171.4, 169.5, 2 × 21.2), and a tigloyl (δH 6,50 q, 1.28
d, 1.23 s; δC 166.6, 137.8, 128.1, 14.3, and 11.4) group (Tables
1 and 2). In combination with the 1H and 13C NMR data, the
molecular formula indicated that 1 is a bicyclic diterpenoid
with a disubstituted (δH 5.65 dd, 5.11 d; δC 138.3, 129.6) and a
trisubstituted (δH 5.69 d; δC 135.1, 119.8) oleﬁnic bond
satisfying the 13 indices of hydrogen deﬁciency. Interpretation
of HSQC cross-peaks allowed the assignment of the polyester
core comprising ﬁve methyls, two methylenes, seven methines
(including four oxymethines), and three oleﬁnic carbons.
Resonances at δC 135.1, 84.0, and 40.2 that did not exhibit any
correlations were classiﬁed as a nonprotonated sp2, an
oxygenated tertiary, and a quaternary carbon, respectively.
Apart from the benzoyl and tigloyl groups, three sequences of
correlated protons were identiﬁed from the 1H−1H-COSY
spectrum: −CH2−CH(CH3)−CH(OR)−CH−CH (δH
2.04 m, 1.74 m, 2.11 m, 0.90 d, 5.38 br s, 2.89 dd, 5.69 d)
[A]; −CH(OR)−CH2−CH(OR)− (δH 5.08 br s, 1.99 m, 4.86
br s) [B]; and −CHCH−CH(CH3)−CH(OR)− (δH 5.11
d, 5.65 dd, 2.56 m, 0.94 d, 4.91 d) [C] (Figure 1).
Additionally, a weak 4JH,H (W-type) interaction between the
protons resonating at δH 5.69 and 1.75 implied their close
proximity in the diterpenoid scaﬀold. The connectivities of
COSY spin systems were established by an HMBC experiment.
2JC,H and
3JC,H couplings of H-1α, H-1β, H-3, H-4, and C-15,
together with H-14/C-1, revealed the presence of a cyclo-
pentane moiety and the linkage of subunits A and C through
C-15. Long-range correlations between H-9, H-12, H3-18, H3-
19, and C-10 demonstrated that structural fragments B and C
and two geminal methyls are involved in the formation of a 12-
membered macrocycle characteristic of the jatrophane
diterpenoid core. The lack of exomethylene signals and strong
cross-peaks of the deshielded H3-17 with C-5, C-6, and C-7
unambiguously proved that compound 1 contains a rare Δ5(6)
oleﬁnic bond instead of the regular Δ6(17) double bond. The
locations of the ester functionalities were determined via 3JC,H
interactions of skeletal oxymethine protons H-3, H-7, H-9, and
H-14 with carbonyl carbons at δC 165.8 (benzoyl), 166.6
(tigloyl), 169.5, and 171.4 (acetyls), respectively. The relative
conﬁguration was deﬁned by analyzing the NOESY spectrum
and the pattern of coupling constants. NOE correlations of the
reference H-4α with H-2, H-3, H-13, and H-14 conﬁrmed the
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β-orientation of the secondary methyls H3-16 and H3-20, the
C-3 benzoyl group, and the C-14 acetyl group. The C-1
geminal proton pair were readily distinguished via the H-1α/
H-14 and H-1β/H3-16 interactions. The large coupling
constant between H-4 and H-5 (3JH4,5 = 10.4 Hz) conﬁrmed
their location on the opposite sides of the molecule.21 With
regard to diagnostic NOE-enhanced signals of H-4/H3-17 and
H-5/H-9, as well as the absence of a H-5/H3-17 correlation,
the trisubstituted Δ5(6) oleﬁnic bond must have an E-
conﬁguration.22 Important cross-peaks of H-7/H3-17 and H-
9/H3-18 clearly dictated the β-position of the tigloyl and the α-
orientation of the acetyl groups located at C-7 and C-9,
respectively. Furthermore, the E-conﬁguration of the Δ11(12)
double bond was evident from the large 3JH11,12 value (15.8
Hz). The 12-membered macrocycles are known to be quite
ﬂexible; however, concerning the sharp proton signals it is
most likely that molecules were undergoing fast interconver-
sions between two or more conformations in solution.
Considering the large value of 3JH4,5 and the restricted rotation
around the C-5/C-6 axis, it was clear that the H3-17 methyl is
predominantly orthogonal to the mean plane of the macro-
cycle, implying that compound 1 preferentially adopted an
endo-type conformation.21,23
The absolute conﬁguration of compound 1 was determined
by single-crystal X-ray diﬀraction. Single crystals of size around
0.05 × 0.1 × 2−3 mm were grown from a mixture of
acetonitrile and water. The saturated solution was seeded by
minuscule crystals obtained from the melt of the compound
Table 1. 1H NMR Data of Compounds 1−9 at 500 MHz (δH in ppm, J in Hz)
position 1a 2b 3b 4a 5a 6c 7a 8a 9a
1α 2.04, m 2.10, dd (12.9,
7.1)
2.12, dd (12.9,
7.2)
2.06, m 2.03, dd (13.2,
6.7)
2.52, dd (12.3,
6.5)
2.06, dd (13.0,
6.5)
2.08, dd (12.6,
6.6)
2.95, br d
(7.0)
1β 1.74, m 1.72, t (12.9) 1.70, t (12.9) 1.70, t (12.9) 1.74, t (12.9) 2.19, t (12.3) 1.75, t (13.0) 1.73, m 2.14, mo
2 2.11, m 2.12, m 2.20, m 2.14, m 2.16, m 2.27, m 2.13, m 2.14, m 2.14, mo
3 5.38, br s 5.35, br t (3.6) 5.36, br t (3.6) 5.39, br t (4.2) 5.41, br t (4.3) 5.79, br s 5.42, br s 5.38, br s 5.41, dd (3.9,
2.5)
4 2.89, dd (10.4,
4.8)
3.11, dd (10.0,
4.5)
3.11, dd (10.0,
4.6)
2.97, dd (10.5,
5.1)
2.98, dd (10.5,
5.1)
3.22, dd (9.8,
4.7)
2.84, dd (9.8,
4.5)
2.88, dd (10.0,
4.6)
2.99, dd (9.8,
3.9)
5 5.69, d (10.4) 5.85, br d
(9.3)
5.87, br d
(8.9)
5.94, d (10.5) 5.94, d (10.5) 6.33, d (9.8) 5.63, br d
(8.8)
5.66, d (10.0) 5.75, d (9.8)
7 5.08, br s 5.08, br s 5.10, br s 3.99, d (3.4) 4.01, br d
(3.2)
5.51, br s 5.04, br s 4.15, br s 4.96, br s
8 1.99, m (2H) 5.14, br s 5.16, br s 5.15, d (4.0) 5.17, d (4.4) 4.28, d (8.2) 3.71, br s 3.58, br s 5.07, br so
9 4.86, br s 5.31, br s 5.32, br s 4.54, d (3.8) 4.53, d (4.2) 5.63, br s 3.33, br d
(5.5)
3.36, br s 5.07, br so
11 5.11, d (15.8) 5.10, d (15.7) 5.13, d (15.7) 5.12, d (15.7) 5.11, d (15.6) 5.34, d (15.8) 5.04, d (15.4) 5.06, d (15.7) 5.09, d (15.7)
12 5.65, dd (15.8,
9.0)
5.97, dd (15.7,
8.5)
5.99, dd (15.7,
8.5)
5.65, dd (15.7,
9.2)
5.65, dd (15.6,
9.3)
6.38, dd (15.8,
8.4)
5.63, dd (15.4,
8.8)
5.61, dd (15.7,
8.9)
5.57, dd (15.7,
8.6)
13 2.56, m 2.68, m 2.71, m 2.62, m 2.62, dq (6.9,
9.3)
2.85, m 2.49, m 2.51, m 2.41, m
14 4.91, d (2.2) 4.95, d (2.6) 5.01, d (2.5) 4.97, d (2.5) 4.94, d (2.8) 5.31, br s 4.92, br s 4.90, br s 3.54, t (2.6)
16 0.90, d (6.4) 0.88, d (6.6) 0.88, d (6.6) 0.95, d (6.7) 0.98, d (6.7) 1.01, d (6.4) 0.96, d (6.6) 0.96, br d
(6.1)
0.99, d (5.7)
17 1.75, s 1.89, s 1.90, s 1.78, s 1.80, s 1.92, s 1.80, s 1.74, s 1.87, s
18 0.93, s 0.98, s 0.99, s 1.03, s 1.05, s 1.22, s 1.12, s 1.09, s 0.93, s
19 0.87, s 0.86, s 0.87, s 0.91, s 0.93, s 1.29, s 0.83, s 0.86, s 0.85, s
20 0.94, d (7.5) 0.95, d (7.0) 0.93, d (6.9) 0.93, d (7.0) 0.95, d (6.9) 1.17, d (6.5) 0.96, d (6.6) 0.96, br d
(6.1)
1.14, d (7.0)
OBz-3 7.98, d (7.4) 7.99, d (7.4) 7.99, d (7.4) 8.03, d (7.4) 8.05, d (7.4) 8.26, d (7.8) 8.04, d (7.8) 8.02, d (7.5) 7.99, d (7.4)
7.38, t (7.6) 7.44, t (7.7) 7.44, t (7.8) 7.40, t (7.8) 7.43, t (7.8) 7.25, t (7.5) 7.43, t (7.5) 7.43, t (7.3) 7.45, t (7.6)
7.49, t (7.2) 7.58, t (7.4) 7.57, t (7.5) 7.50, t (7.4) 7.52, t (7.4) 7.42, t (7,2) 7.53, t (7.3) 7.54, t (7.3) 7.56, t (7.4)
R1-7 −OTig −OTig −OTig −OH −OH −OAc −OAc −OH −OAc
6.50, q (6.6) 6.57, q (6.3) 6.57, q (6.8) 3.78, br s 3.90, br s 1.32, s 1.25, s n.o. 1.12, s
1.28, d (6.8) 1.31, br d
(5.7)
1.30, br d
(5.7)
1.23, s 1.24, s 1.25, s
R2-8 −OAc −OAc −OAc −OAc −OH −OH −OH −OAc
2.04, br s 2.04, br s 2.03, s 2.05, s 5.70, d (8.2) 4.12, br s n.o. 2.04, s
R3-9 −OAc −OAc −OAc −OAc −OAc −OAc −OH −OH −OAc
1.86, s 1.99, s 1.99, s 2.09, s 2.10, s 2.13, s 2.70, d (7.2) n.o. 2.06, s
R4-14 −OAc −OAc −OTig −OTig −OAc −OAc −OAc −OAc −OH
2.19, s 2.20, s 7.07, dq (6.9,
0.9)
6.96, dq (6.9,
1.1)
2.26, s 2.12, s 2.23, s 2.23, s 4.93, d (2.6)
1.87, d (6.9) 1.83, d (6.9)
1.92, br s 1.89, br s
R5-15 −OH −OH −OH −OH −OH −OH −OH −OH −OAc
n.o. n.o. n.o. n.o. n.o. n.o. n.o. n.o. 2.41, s
aMeasured in CDCl3.
bMeasured in methanol-d4.
cMeasured in pyridine-d5.
oOverlapping signals; n.o.: not observed.
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(see details in the Supporting Information). When a traditional
sealed tube X-ray source is used, reﬂections of the transparent,
needle-like crystals were weak. A higher intensity beam was
necessary in order to measure high-angle reﬂections; therefore
data collection was performed on a single crystal of 1 (size 0.02
× 0.02 × 0.15 mm) at the synchrotron source SOLEIL, on the
PROXIMA 1 beamline (λ = 0.799 90 Å, beam size HxV = 40 ×
30 μm2) at −173 °C in the θ-range of 1.682−31.198°. Details
of crystal and structural data can be found in the Supporting
Information.
Compound 1 crystallizes in the monoclinic chiral space
group P21 with three crystallographically independent but
chemically identical molecules in the asymmetric unit. The
absolute conﬁguration has been established in the diﬀraction
measurement based on the anomalous dispersion eﬀect of the
nine oxygen atoms present in the molecule. For all three
conformers of 1 , the assignment is most l ikely
(2S,3S,4S,7R,9R,13S,14S,15R)-9α,14β-diacetoxy-3β-benzoyl-
oxy-15β-hydroxy-7β-tigloyloxyjatropha-5E,11E-diene (Figure
2). Thus, all three crystallographically independent molecules
in the asymmetric unit have the same conﬁguration (Figure 3).
The cyclopentane rings constructed by C-1, C-2, C-3, C-4,
and C-15 are in an envelope form with C-2 extending above
the plane by the closest puckering descriptors in rings
indicated by C-1 and C-1″, while twisted on C-2′−C-3′ in
the ring indicated by C-1′ (the three chemically identical but
Table 2. 13C NMR Data of Compounds 1−9 at 125 MHz (δC in ppm)
position 1a 2b 3b 4a 5a 6c 7a 8a 9a
1 46.2 48.8 48.5 46.4 46.3 48.4 46.9 46.6 44.9
2 37.4 38.3 38.4 36.9 37.0 37.4 36.9 37.1 37.9
3 81.0 82.9 82.9 81.3 81.2 82.0 81.1 81.5 79.9
4 48.1 48.7 48.8 48.0 48.0 48.5 47.9 48.1 48.6
5 119.8 124.3 124.4 121.9 122.0 122.8 122.1 120.2 121.1
6 135.1 132.2 132.4 134.8 134.9 131.6 130.7 136.2 131.3
7 73.5 79.5 79.6 77.5 77.5 82.8 81.8 79.9 77.5
8 32.5 69.6 69.6 69.6 69.5 68.3 68.0 68.0 68.0
9 73.9 73.7 73.7 73.5 73.8 74.3 72.4 71.8 72.2
10 40.2 41.0 41.1 39.3 39.5 40.2 40.1 39.8 39.3
11 138.3 135.9 136.1 136.8 136.9 135.6 139.5 139.6 135.5
12 129.6 134.1 134.2 130.3 130.4 133.0 128.8 128.8e 130.5
13 39.5 40.0 40.4 39.7 39.9 39.5 39.7 39.4 39.8
14 81.2 82.6 82.6 81.0 81.1 81.6 80.9 81.0 81.1
15 84.0 84.3 84.6 84.4 84.5 83.8 84.1 84.3 94.8
16 13.9 14.2 14.2 13.9 13.9 14.3 13.6 13.9 13.3
17 16.7 16.6 16.6 16.1 16.2 16.8 16.6 16.7 15.8
18 22.9 23.5 23.4 22.8 22.8 23.5 22.9 23.1 22.0
19 20.5 21.3 21.3 21.0 21.0 21.7 19.0 19.2 19.4
20 19.4 20.2 20.0 19.3 19.4 20.4 19.9 19.5 20.4
BzO-3 165.8 167.3 167.4 166.5 166.7 166.1 165.6 166.4 164.9
130.4 131.6 131.6 130.6 130.8 131.4 130.3 130.2 129.9
130.0 131.0 131.0 130.0 129.9 130.6 129.9 129.9 129.5
128.5 129.7 129.7 128.6 128.6 129.0 128.7 128.8e 128.5
132.8 134.2 134.2 133.0 133.0 133.3 133.2 133.3 133.1
TigO-7 166.6 168.2 168.2
128.1 128.7 128.7
137.8 139.7 139.8
14.3 14.5 14.5
11.4 12.0 12.0
AcO-7 170.0 172.5 168.9
20.3 19.8 20.1
AcO-8 172.0 172.1 169.7 169.9 170.2
21.0e 21.1e 21.2 21.2 21.0
AcO-9 169.5 171.6 171.6 172.1 172.2 169.6 169.2
21.2e 21.0e 21.1e 20.9 20.9 21.2e 20.8
AcO-14 171.4 173.3 171.2 171.8 171.3 171.3
21.2e 21.1 21.3 21.2e 21.2 21.2
TigO-14 170.0 168.2
129.8 128.4
139.6 138.4
14.7 14.9
12.5 12.1
AcO-15 174.3
22.0
aMeasured in CDCl3.
bMeasured in methanol-d4.
cMeasured in pyridine-d5.
eExchangeable signals.
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crystallographically independent molecules (Z′ = 3) are labeled
without a prime, with one prime, and with two primes,
respectively). The angles of the ﬁve-membered ring and the
aromatic ring in the independent molecules are 69.9(2)°,
82.0(3)°, and 64.5(2)°, respectively. The conformational
diﬀerences of the core of the molecules are not large in spite
of the potential ﬂexibility of the 12-membered macrocycle.
Superimposing the core ring systems of the three molecules ﬁts
well (Figure 3A), and the atomic positions in the terminal part
of the substituents diﬀer (Figure 3B).
Compound 2 was obtained as a white, amorphous solid. Its
HRESIMS spectrum exhibited a sodium adduct ion at m/z
705.3281 [M + Na]+ (calcd 705.3251), indicating the
molecular formula C38H50O11. Comparison of the spectro-
scopic data of 1 and 2 showed that the structures diﬀered only
in an acetoxy group (Tables 1 and 2). This conclusion was
substantiated by the presence of an sp3 oxymethine and methyl
resonances at δH 5.14 and δH 2.04, which gave HMBC
correlations with a carbonyl carbon at δC 172.0. Further long-
range couplings of H-7/C-8, H-8/C-9, and H-8/C-10
suggested that the acetoxy moiety is attached to C-8.
Moreover, the zero or small coupling constants 3JH7,8 and
3JH8,9 are characteristic features of the 7,8,9-trisubstituted
jatrophane derivatives.22,23 The β-orientation of 8-OAc was
proven by NOE cross-peaks of H-8 with H3-17 and H3-19,
while the other eight stereogenic centers were found to be
identical with those of compound 1.
Compound 3 was obtained as a white, amorphous powder.
Its molecular formula was deduced to be C41H54O11 from the
HRESIMS sodium adduct ion at m/z 745.3596 [M + Na]+
(calcd 745.3564). Comprehensive analysis of 1H, JMOD, and
2D data indicated the presence of the same parent system and
esteriﬁcation pattern as in compound 2, with the exception of
C-14, on which the acetyl group was replaced by an tigloyloxy
moiety (Tables 1 and 2). Proton signals of 7-OTig (δH 6.57 q,
1.30 br d, 1.25 s) were signiﬁcantly shielded compared to those
of 14-OTig (7.07 dq, 1.92 br s, 1.87 d), which was caused by
the anisotropic eﬀect of the cis-located C-3 aromatic
substituent.24 The relative conﬁgurations of stereogenic
carbons were determined by means of a NOESY experiment.
Compound 4 was isolated as white granules, and its formula
was assigned as C36H48O10 in accordance with the HRESIMS
sodium adduct ion at m/z 663.3172 [M + Na]+ (calcd
663.3145). The lack of diamagnetic shifted signals attributed to
7-OTig and an additional hydrogen resonance at δH 3.78 with
no HSQC cross-peak demonstrated that the diﬀerence
between 4 and 3 involved the absence of the acyl residue at
Figure 1. Key 2D NMR correlations for 1. Bold bonds indicate
COSY; arrows indicate HMBC (H → C) correlations.
Figure 2. Molecular structure of compound 1 with atomic labeling.
The displacement ellipsoids are drawn at the 50% probability level.
Figure 3. Panel A shows the unit cell of 1. Panel B represents the molecular overlay of the three crystallographically independent conformers of 1.
[The molecules in the asymmetric unit are distinguished by colors: yellow (C1), green (C1′), and purple (C1″).]
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C-7 (Tables 1 and 2). NOE interactions of this hydroxy proton
with H-9, as well as H-7/H-8 and H-7/H3-17, permitted
assignment of the same conﬁguration as in 3.
Compound 5, C33H44O10, was shown to be the 14-O-acetyl
analogue of 4 by the sodium adduct HRESIMS ion at m/z
623.2858 [M + Na]+ (calcd 623.2832) and its 2D NMR
spectra. Heteronuclear 2JC,H and
3JC,H correlations of acyl
methyls (δH 2.05 s, 2.10 s, 2.26 s) and skeletal oxymethines (δH
5.17 d, 4.53 d, 4.94 d) with ester carbonyls (δC 169.9, 172.2,
171.2) (Tables 1 and 2) provided key information regarding
the exact location of substituents. Similar considerations led to
the determination of compound 6 as an isomer of 5, possessing
the hydroxy group at C-8 instead of C-7 (Tables 1 and 2).
Compound 7, C31H42O9, could be derived from 6 by the loss
of an acetyl unit compatible with the sodiated HRESIMS ion at
m/z 581.2732 [M + Na]+ (calcd 581.2766). Evaluation of the
HMBC spectrum in conjunction with mutual 1H−1H-COSY
couplings of vicinal hydroxy groups (δH 4.12 br s, 2.70 d) with
neighboring H-8 and H-9 methines (δH 3.71 br s, 3.33 br d)
established the ﬁnal structure bearing acetoxy groups at C-7
and C-14 (Tables 1 and 2). The spatial orientation of 7-OAc in
the shielding cone of the C-3 cis-benzoyl group was apparent
from its diamagnetic shifted protons compared to 14-OAc
hydrogens (1.25 and 2.23 s, respectively). The molecular
formula of 8 was assigned as C29H40O8 using the sodium
adduct ion [M + Na]+ observed at m/z 539.2644 [M + Na]+
(calcd 539.2621). 1H and JMOD NMR spectra showed
corresponding signals for only one acetoxy group that, based
on HMBC cross-peaks of H-14 (δH 4.90 br s) and the ester
methyl (δH 2.23 s) with a carbonyl carbon at δC 171.3 (Tables
1 and 2), must be attached to C-14.
Compound 9 has the molecular formula C35H46O11,
determined by the HRESIMS sodium adduct ion at m/z
665.2960 [M + Na]+ (calcd 665.2938). The major diﬀerences
between 9 and jatrophanes 1−8 were the remarkable
paramagnetic shifts of the C-1 geminal protons (δH 2.95 br
d, 2.14 m), the acetyl resonance at δH 2.41, and the oxygenated
tertiary C-15 at δC 94.8 (Tables 1 and 2). In order to deﬁne
the structure, a complete series of 2D NMR spectra were
recorded and analyzed. Compound 9 is a structural isomer of
the known euphomelliferene B,22 in which the ester and
hydroxy substituents at C-14 and C-15 were interchanged.
This unusual feature was conﬁrmed by the COSY correlation
between H-14 (δH 3.54 t) and a hydroxy signal (δH 4.93 d)
and by the absence of HMBC cross-peaks of the acetyl
carbonyl carbon (δC 174.3) with skeletal protons. A set of
NOE eﬀects revealed the same relative conﬁguration of the
stereogenic carbons. Given the fact that all of the jatrophane
diterpenoids isolated to date contain a trans-fused cyclo-
pentane ring, the 15-OAc moiety is assumed to occupy a β-
position.25
According to the literature data, compounds 10 and 11 were
identiﬁed as euphomelliferene B and euphornin, respec-
tively.22,26
Eﬀects of Compounds on GIRK and hERG Potassium
Channels. In order to ﬁnd eﬀective natural agents for the
treatment of atrial ﬁbrillation, screening of the diterpenoids
with diﬀerent skeletons and substitution patterns isolated from
E. dulcis (1−11) and E. taurinensis (12−16) was performed on
the GIRK channel expressing cell line. Compounds were
screened in two concentrations (1 and 10 μM) on two or three
cells. The majority of the diterpenoids possessed signiﬁcant
blocking activity at 10 μM concentration on the GIRK
channel, and some of these compounds exhibited notable
inhibitory eﬀects even at a 1 μM concentration (Table 3).
Compounds 1, 2, 9−11, 13, and 14, showing the most
intense GIRK inhibitory activities at 1 μM concentration, were
subjected to further investigations. The dose−response curves
of these seven compounds were determined in detailed
experiments where the eﬀect of the compounds was tested in
four concentrations on ﬁve or six cells. The GIRK current was
considerably reduced by these diterpenoids in a concentration-
dependent manner. The eﬀects on the inward current were
statistically signiﬁcant in all tested concentrations of the seven
substances. Dose−response curves and IC50 values of the
investigated compounds are shown in Figure 4.
Compounds 1 and 14 were the most eﬀective diterpenoids,
with IC50 values of 1.3 ± 0.2 and 1.5 ± 0.1 μM, respectively.
The IC50 values of compounds 2 and 10 were similar (1.6 ±
0.2 and 1.7 ± 0.2 μM, respectively). The IC50 values of
compound 11 were 2.6 ± 0.5 μM, of compound 9 3.4 ± 0.1
μM, and for compound 13 12.2 ± 0.5 μM. Original GIRK
current curves during the application of diﬀerent concen-
trations of the most eﬀective compounds (compounds 1 and
14) are shown in Figures 5A and 6A.
Compounds 1, 2, 9−11, 13, and 14 were also tested on the
HEK-hERG cell line, and selectivity of their GIRK blocking
eﬀect was evaluated. Selectivity studies were performed in two
concentrations (1 and 10 μM) on two cells. Compound 14
exerted a remarkable inhibitory eﬀect on the hERG channel at
a 10 μM concentration, while the other test compounds
exhibited only minor eﬀects (Table 4). However, these slight
reductions of the current amplitudes were presumably and
partly the consequence of the run-down phenomenon (slight
and spontaneous decrease of the current). Original hERG
current sweeps during the application of compounds 1 and 14
at 1 and 10 μM concentrations are shown in Figures 5B and
6B.
Table 3. Electrophysiological Eﬀects of Compounds 1−16
on GIRK Current in HEK-GIRK Cellsa
GIRK inhibition (%)
concentration propafenone
compound 1 μM 10 μM 1 μM
1 35.5 ± 5.6 88.7 ± 2.4 93.2 ± 1.7
2 38.5 ± 3.5 85.0 ± 0.8 92.6 ± 3.2
3 23.5 ± 0.3 35.7 ± 7.4 70.1 ± 5.9
4 15.3 ± 2.7 60.8 ± 6.8 60.6 ± 2.6
5 16.8 ± 2.1 66.6 ± 3.5 64.2 ± 2.5
6 16.0 ± 10.2 26.8 ± 6.9 65.2 ± 3.4
7 11.2 ± 6.3 23.5 ± 3.3 72.7 ± 1.5
8 15.7 ± 9.0 25.7 ± 1.7 69.4 ± 3.0
9 27.2 ± 4.8 66.0 ± 8.2 76.3 ± 6.7
10 33.8 ± 4.9 83.4 ± 0.6 94.2 ± 2.4
11 31.1 ± 1.9 78.7 ± 6.1 74.7 ± 6.2
12 22.2 ± 5.8 23.7 ± 8.1 61.2 ± 2.5
13 23.8 ± 11.4 52.3 ± 5.4 75.8 ± 2.5
14 43.9 ± 13.8 80.4 ± 0.3 83.8 ± 1.4
15 16.4 ± 4.3 45.1 ± 5.4 70.6 ± 1.2
16 17.7 ± 1.3 28.6 ± 2.8 68.0 ± 5.0
aResults are means ± SEM, n = 2, 3.
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■ EXPERIMENTAL SECTION
General Experimental Procedures. The melting point of
compound 1 was measured on a Linkam hot stage microscope
(temperature range of −180 to 400 °C), and its thermal behavior was
investigated by means of a Mettler-Toledo diﬀerential scanning
calorimeter (operational range between −80 and 400 °C). Optical
rotations were measured in CHCl3 using a PerkinElmer 341
polarimeter. NMR spectra were recorded on a Bruker Avance DRX
500 spectrometer at 500 MHz (1H) and 125 MHz (13C). The residual
peaks of the deuterated solvents were taken as reference points. The
data were acquired and processed with MestReNova v6.0.2−5475
software. Chemical shifts are expressed in parts per million, and
coupling constant (J) values are reported in Hz. High-resolution MS
data were recorded on a Thermo Q Exactive Plus orbitrap mass
spectrometer equipped with an ESI source and coupled with an
Figure 4. Dose−response curves of compounds 1, 2, 9−11, 13, and 14 on GIRK current. Data are expressed as means ± SEM values, n = 5, 6.
Figure 5. Eﬀects of compound 1 on GIRK and hERG current. Panel A shows representative GIRK current curves recorded during the application
of 0.3, 1, 3, and 10 μM compound 1. The inset shows the applied GIRK voltage protocol. Application of compound 1 inhibited the GIRK current
in a dose-dependent manner. The data were corrected with the current value measured in the K+-free external solution, which served as the
baseline. Panel B depicts typical hERG current sweeps during the application of 1 and 10 μM compound 1. The inset shows the applied hERG
voltage protocol. The original current traces show that compound 1 very slightly and not signiﬁcantly blocked the hERG channel, while addition of
reference compound amitriptyline (10 μM) fully blocked the current.
Figure 6. Concentration-dependent inhibitory eﬀects of compound 14 on GIRK and hERG current. Panel A shows typical current curves obtained
from HEK-GIRK cells treated with 0.3, 1, 3, and 10 μM compound 14. The inset shows the applied GIRK voltage protocol. The data were
corrected with the current value measured in the K+-free external solution, which served as the baseline. Panel B shows example traces for hERG-
mediated whole-cell current. Cells were treated with 1 and 10 μM compound 14. Compound 14 very slightly and not signiﬁcantly blocked the
hERG channel at 1 μM concentration, while addition of 10 μM compound 14 signiﬁcantly inhibited the current. The inset shows the applied hERG
voltage protocol.
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Agilent 1100 HPLC system. The samples were measured with the
ﬂow injection analysis (FIA) method. The mass spectrometer was
working in positive mode, and the scan mass range was set to m/z
150−2000 at a resolution of 140 000. The data were acquired and
processed with Thermo Xcalibur 4.0 software. For column
chromatography, polyamide (MP Polyamide, 50−160 μm, MP
Biomedicals), silica gel (silica gel GF254, 15 μm, Merck), and
reversed-phase silica (LiChroprep RP-18, 40−63 μm, Merck) were
used. HPLC was carried out on a Waters Millipore instrument with
UV detection at 254 nm over normal phase (LiChrospher Si 100, 5
μm, 250 × 4 mm) and reversed-phase (LiChrosper RP-18, 5 μm, 250
× 4 mm) columns. Preparative TLC was performed on aluminum
sheets coated with normal (TLC silica gel 60 F254, Merck) and
reversed-phase (TLC silica gel 60 RP-18 F254S, Merck) silica.
Plant Material. The plant was collected at Homorod́almaś,
Romania, in July 2014 and was identiﬁed by one of the authors, G.J. A
voucher specimen (No. 838) has been deposited in the Herbarium of
the Department of Pharmacognosy, University of Szeged, Szeged,
Hungary.
Extraction and Isolation. The frozen whole plant of E. dulcis
(3800 g) was crushed in a blender and percolated with MeOH (30 L)
at room temperature. The crude extract was concentrated in vacuo
and exhaustively extracted with CHCl3 (5 × 500 mL). The organic
phase gave a residue (33.6 g), which was chromatographed on a
polyamide column (160 g) with mixtures of MeOH and H2O (3:2
and 4:1, 4.5, and 2.2 L, respectively) as eluents. The fraction obtained
with MeOH−H2O (3:2) was subjected to silica gel vacuum liquid
chromatography (VLC) using a gradient solvent system of cyclo-
hexane−EtOAc−EtOH (70:10:0, 60:10:0, 50:10:0, 50:10:1, 40:10:1,
30:10:1, and 20:10:1; each 200 mL) to yield 55 fractions (each 25
mL). The eluates were monitored by TLC. Fractions with the same
chromatographic proﬁle were combined. Pooled fraction 21−32,
obtained with cyclohexane−EtOAc−EtOH (50:10:1) was further
separated by reversed-phase silica gel column chromatography (A)
with step gradient of mobile phase composed of MeOH−H2O (6:4,
7:3, 8:2, 10:2, and 10:1; each 100 mL) to give 45 subfractions (A1−
45, each 10 mL). Puriﬁcation of A20 was carried out by means of RP-
HPLC (ﬂow rate: 1.5 mL/min, MeCN-H2O 7:3, isocratic elution).
Peaks eluted at retention times of 6.8 and 8.5 min aﬀorded compound
11 (23.1 mg) and 2 (83.0 mg). Separation of A21−25 was performed
under the same conditions and resulted in the isolation of compound
1 (tR: 11.5 min, 177.4 mg) and an additional portion of 2 (35.3 mg).
Fraction A29−36 was subjected to preparative TLC using toluene−
Me2CO (10:2) as mobile phase to yield compound 3 (9.4 mg).
Fraction 38−47, eluted with cyclohexane−EtOAc−EtOH (30:10:1)
was transferred to a reversed-phase silica gel column (B) using a
stepwise gradient of MeOH−H2O mixtures (5:5, 6:4, 7:3, 8:2, and
9:1; each 200 mL) to aﬀord 62 subfractions (B1−62, each 15 mL).
Fraction B32−42 was further fractionated by VLC (C) on silica gel
with increasing polarity of toluene−CHCl3−acetone (70:10:1, 50 mL;
60:10:1, 50 mL; 50:10:1, 50 mL; 40:10:1, 50 mL; 30:10:1, 100 mL;
20:10:1, 100 mL; 10:10:1, 50 mL) to furnish 27 eluates (C1−27, each
15 mL). Fractions C6−7 and C8−10 were chromatographed by RP-
HPLC (ﬂow rate: 1.5 mL/min, MeCN−H2O, 6:4, isocratic elution)
to give compounds 10 (8.2 mg) and 9 (8.0 mg) observed at retention
times of 7.2 and 8.0 min, respectively. The ﬁnal steps of purifying
fraction C11−24 involved consecutive techniques of preparative TLC
with the use of a cyclohexane−CHCl3−MeOH (15:10:1) mobile
phase and RP-HPLC (ﬂow rate: 1.5 mL/min, MeCN−H2O 1:1,
isocratic elution). Peaks collected at retention times of 9.2, 12.5, and
17.4 min yielded pure compounds 8 (8.5 mg), 7 (16.8 mg), and 6
(22.1 mg), respectively. Compounds 4 (3.2 mg) and 5 (5.1 mg) were
isolated from fraction B49−56 after repetitive puriﬁcation by
preparative TLC over normal- and reversed-phase silica gel employing
mobile phases of toluene−acetone (4:1) and MeOH−H2O (11:2),
respectively.
(2S,3S,4S,7R,9R,13S,14S,15R)-9α,14β-Diacetoxy-3β-benzoyloxy-
15β-hydroxy-7β-tigloyloxyjatropha-5E,11E-diene (1): colorless, nee-
dle-like material; mp of the minuscule needles obtained from the melt
of the compound (in Supporting Information) 141.5 °C; [α]26D −26
(c 0.3, CHCl3); for
1H and 13C NMR spectroscopic data, see Tables 1
and 2; HRESIMS m/z 625.3371 [M + H]+ (calcd for C36H49O9
625.3377).
8β,9α,14β-Triacetoxy-3β-benzoyloxy-15β-hydroxy-7β-tigloyloxy-
jatropha-5E,11E-diene (2): white, amorphous solid; [α]27D −196 (c
0.2, CHCl3); for
1H and 13C NMR spectroscopic data, see Tables 1
and 2; HRESIMS m/z 705.3281 [M + Na]+ (calcd for C38H50O11Na
705.3251), 721.3019 [M + K]+ (calcd for C38H50O11K 721.2990) and
700.3731 [M + NH4]
+ (calcd for C38H54O11N 700.3697).
8β,9α-Diacetoxy-3β-benzoyloxy-15β-hydroxy-7β,14β-ditigloy-
loxyjatropha-5E,11E-diene (3): white, amorphous powder; [α]27D
−18 (c 0.3, CHCl3); for 1H and 13C NMR spectroscopic data, see
Tables 1 and 2; HRESIMS m/z 745.3596 [M + Na]+ (calcd for
C41H54O11Na 745.3564), 761.3333 [M + K]
+ (calcd for C41H54O11K
761.3303) and 740.4048 [M + NH4]
+ (calcd for C41H58O11N
740.4010).
8β,9α-Diacetoxy-3β-benzoyloxy-7β,15β-dihydroxy-14β-tigloy-
loxyjatropha-5E,11E-diene (4): white, amorphous powder; [α]27D
−11 (c 0.2, CHCl3); for 1H and 13C NMR spectroscopic data, see
Tables 1 and 2; HRESIMS m/z 663.3172 [M + Na]+ (calcd for
C36H48O10Na 663.3145), 679.2909 [M + K]
+ (calcd for C36H48O10K
679.2885) and 658.3623 [M + NH4]
+ (calcd for C36H52O10N
658.3591).
8β,9α,14β-Triacetoxy-3β-benzoyloxy-7β,15β-dihydroxyjatropha-
5E,11E-diene (5): white, amorphous powder; [α]26D −11 (c 0.2,
CHCl3); for
1H and 13C NMR spectroscopic data, see Tables 1 and 2;
HRESIMS m/z 623.2858 [M + Na]+ (calcd for C33H44O10Na
623.2832), 639.2596 [M + K]+ (calcd for C33H44O10K 639.2572) and
618.3308 [M + NH4]
+ (calcd for C33H48O10N 618.3278).
7β,9α,14β-Triacetoxy-3β-benzoyloxy-8β,15β-dihydroxyjatropha-
5E,11E-diene (6): white, amorphous powder; [α]26D −10 (c 0.2,
CHCl3); for
1H and 13C NMR spectroscopic data, see Tables 1 and 2;
HRESIMS m/z 623.2816 [M + Na]+ (calcd for C33H44O10Na
623.2832), 618.3263 [M + NH4]
+ (calcd for C33H48O10N 618.3278)
and 583.2891 [M − H2O + H]+ (calcd for C33H43O9 583.2907).
7β,14β-Diacetoxy-3β-benzoyloxy-8β,9α,15β-trihydroxyjatropha-
5E,11E-diene (7): white, amorphous powder; [α]26D −27 (c 0.2,
CHCl3); for
1H and 13C NMR spectroscopic data, see Tables 1 and 2;
HRESIMS m/z 581.2732 [M + Na]+ (calcd for C31H42O9Na
581.2727), 597.2466 [M + K]+ (calcd for C31H42O9K 597.2466).
14β-Acetoxy-3β-benzoyloxy-7β,8β,9α,15β-tetrahydroxyjatro-
pha-5E,11E-diene (8): white, amorphous powder; [α]26D −41 (c 0.1,
CHCl3); for
1H and 13C NMR spectroscopic data, see Tables 1 and 2;
HRESIMS m/z 539.2644 [M + Na]+ (calcd for C29H40O8Na
539.2621), 555.2376 [M + K]+ (calcd for C29H40O8K 555.2360)
and 534.3087 [M + NH4]
+ (calcd for C29H44O8N 534.3067).
7β,8β,9α,15β-Tetraacetoxy-3β-benzoyloxy-14β-hydroxyjatro-
pha-5E,11E-diene (9): white, amorphous powder; [α]26D +5.5 (c 0.4,
CHCl3); for
1H and 13C NMR spectroscopic data, see Tables 1 and 2;
HRESIMS m/z 665.2960 [M + Na]+ (calcd for C35H46O11Na
665.2938) and 660.3411 [M + NH4]
+ (calcd for C35H50O11N
660.3384).
Automated Planar Patch-Clamp Measurements. GIRK and
hERG ion currents were measured using the planar patch-clamp
Table 4. hERG Inhibitory Eﬀects of Compounds 1, 2, 9−11,
13, and 14a
hERG inhibition (%)
concentration amitriptyline
compound 1 μM 10 μM 10 μM
1 10.8 ± 5.7 24.9 ± 6.4 97.7 ± 0.8
2 6.5 ± 5.2 24.4 ± 2.0 99.1 ± 0.9
9 11.2 ± 0.6 22.7 ± 2.6 99.3 ± 0.7
10 13.2 ± 2.2 24.0 ± 1.8 98.1 ± 0.5
11 3.3 ± 1.5 19.0 ± 0.5 99.3 ± 0.7
13 1.8 ± 0.4 7.9 ± 1.0 99.2 ± 0.8
14 11.2 ± 0.1 55.4 ± 0.4 100.0 ± 0.0
aResults are means ± SEM, n = 2.
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technology as described by Vasas et al.16 The pipetting protocols were
controlled by PatchControlHT 1.09.30 software (Nanion Technolo-
gies GmbH, Munich, Germany). Data acquisition and online analysis
were performed with an EPC-10 Quadro patch-clamp ampliﬁer
(HEKA Elektronik Dr. Schulze GmbH, Lambrecht/Pfalz, Germany),
using PatchMaster 2.65 software (HEKA Elektronik Dr. Schulze
GmbH, Lambrecht/Pfalz, Germany). Currents were low-pass ﬁltered
at 2.9 kHz using the internal Bessel ﬁlter of the ampliﬁer and digitized
at 10 kHz.
GIRK Channel Inhibitory Assay. Experiments were carried out
on HEK-293 (human embryonic kidney) cells stably expressing the
GIRK1/4 (Kir3.1/3.4) K+ channels by adapting a method described
earlier.16,27
hERG Channel Inhibitory Assay. hERG measurements were
performed on HEK-293 cells stably transfected with cDNA encoding
the hERG (Kv11.1) K+ channel as described earlier.16,28 Increasing
concentrations of the test compound (1 and 10 μM, respectively)
were applied.
Statistics. All data are expressed as arithmetic means ± standard
error (SEM). Statistical analysis was performed with Student’s t test
for paired data and corrected using the Holm−Bonferroni method.
Diﬀerences were considered statistically signiﬁcant when the P value
was less than 0.05.
Single-Crystal Diﬀraction. Crystal data of 1: C36H48O9, fw:
1874.22, colorless needle, size: 0.15 × 0.02 × 0.02 mm, monoclinic,
space group P21, a = 14.1355(4) Å, b = 18.3034(4) Å, c = 20.5777(6)
Å, α = 90°, β = 97.024(3)°, γ = 90°, V = 5284.1(2) Å3, T = 100(2) K,
Z = 2, Z′ = 3, F(000) = 2016, Dx = 1.178 Mg/m3, μ = 0.084 mm−1. A
crystal of 1 was mounted on a Kapton loop. Cell parameters were
determined by least-squares using 31 964 (1.7040° ≤ θ ≤ 30.9450°)
reﬂections. Intensity data were collected at synchrotron SOLEIL at
the PROXIMA 1 beamline (λ = 0.799 90 Å, beam size HxV = 40 × 30
μm2) at 100(2) K in the range of 1.682° ≤ θ ≤ 31.198°. A total of
55 224 reﬂections were collected, of which 19 397 were unique
[R(int) = 0.0477, R(σ) = 0.0387]; intensities of 17 001 reﬂections
were greater than 2σ(I). Completeness to θmax is 0.819. A multiscan
absorption correction was applied to the data (the minimum and
maximum transmission factors were 0.566 83 and 1.000 00). The
structure was solved by direct methods.29 Anisotropic full-matrix
least-squares reﬁnement29 on F2 for all non-hydrogen atoms yielded
R1 = 0.0613 and wR2 = 0.1714 for 1332 [I > 2σ(I)] and R1 = 0.0659
and wR2 = 0.1786 for all (19 397) intensity data, (number of
parameters = 1249, goodness-of-ﬁt = 1.078, the maximum and mean
shift/esd is 0.167 and 0.010 for rotating terminal hydrogen of C17).
The absolute structure parameter is −0.2(5)30 (Friedel coverage:
0.910, Friedel fraction max.: 0.793, Friedel fraction full: 0.946). The
maximum and minimum residual electron density in the ﬁnal
diﬀerence map was 0.478 and −0.310 e Å−3. The weighting scheme
applied was w = 1/[σ2(Fo
2) + (0.131 600 000P)2 + 0.0000P] where P
= (Fo
2 + 2Fc
2)/3. Hydrogen atomic positions were located in
diﬀerence maps. Hydrogen atoms were included in structure factor
calculations, but they were not reﬁned. The isotropic displacement
parameters of the hydrogen atoms were approximated from the U(eq)
value of the atom they were bonded to.
Crystallographic data for compound 1 have been deposited with
the Cambridge Crystallographic Data Centre (deposit no. 1849750).
Copies of the data can be obtained, free of charge, on application to
CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44-(0)
1223-336033 or e-mail: deposite@ccdc.cam.ac.uk).
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(28) Orvos, P.; Viraǵ, L.; Taĺosi, L.; Hajdu,́ Zs.; Csupor, D.;
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